This experiment tests the Viral Trigger Hypothesis in Parkinson's disease by evaluating whether antiviral therapy (valacyclovir) reduces herpes simplex virus type 1 (HSV-1) reactivation events and slows disease progression in early-stage PD patients.
Primary Hypothesis: Chronic/repeated HSV-1 reactivation in the peripheral and central nervous system contributes to neuroinflammation and dopaminergic neurodegeneration in PD. Suppressing viral reactivation with antiviral therapy will reduce inflammatory burden and slow disease progression.
Secondary Hypotheses:
- HSV-1 antibody titers correlate with disease severity and progression rate
- Inflammatory markers (IL-6, TNF-α) will decrease with antiviral therapy
- Patients with higher baseline HSV-1 seropositivity will show greater treatment benefit
Randomized, double-blind, placebo-controlled clinical trial
- Sample size: 200 participants (100 per arm)
- Age: 50-75 years
- Disease stage: Early PD (Hoehn-Yahr 1-2.5)
- Disease duration: ≤3 years from diagnosis
- MMSE: ≥26 (no significant cognitive impairment)
- Clinical diagnosis of Parkinson's disease (UK Brain Bank criteria)
- Age 50-75 years
- Disease duration ≤3 years
- On stable antiparkinsonian medication for ≥4 weeks
- Able to provide informed consent
- Has completed baseline UPDRS, MoCA, and laboratory assessments
- Atypical parkinsonism
- Significant cognitive impairment (MoCA <26)
- History of herpes encephalitis
- Current antiviral therapy use
- Immunosuppressive therapy
- Significant liver or renal disease
- Pregnancy or breastfeeding
- Drug: Valacyclovir (1g twice daily)
- Duration: 12 months
- Rationale: Valacyclovir is a prodrug of acyclovir with better oral bioavailability; suppresses HSV-1 replication and reduces reactivation frequency
- Drug: Placebo (matched tablets)
- Duration: 12 months
| Endpoint |
Measurement |
Timepoints |
| Motor progression |
UPDRS Part III (OFF medication) |
Baseline, 6, 12 months |
| Viral reactivation |
HSV-1 IgG avidity index |
Baseline, 3, 6, 9, 12 months |
| Inflammatory burden |
Serum IL-6, TNF-α |
Baseline, 6, 12 months |
| Endpoint |
Measurement |
Timepoints |
| Non-motor symptoms |
NMSS, PDQ-39 |
Baseline, 6, 12 months |
| Cognitive function |
MoCA |
Baseline, 6, 12 months |
| Autonomic function |
SCOPA-AUT |
Baseline, 6, 12 months |
| Quality of life |
PDQ-39 SI |
Baseline, 6, 12 months |
| Neuroimaging |
DaTSPECT (subset) |
Baseline, 12 months |
- Adverse events (AE/SAE) monitoring
- Liver function tests (ALT, AST)
- Renal function (creatinine, eGFR)
- Complete blood count
- Intent-to-treat population
- Mixed-effects model for repeated measures (MMRM)
- Treatment effect on UPDRS-III change from baseline
- Adjustment for baseline covariates: age, disease duration, baseline UPDRS
- Expected treatment effect: 3 points difference in UPDRS-III (SD=8)
- Power: 80%
- Alpha: 0.05 (two-sided)
- 20% attrition adjustment
- Per-protocol analysis
- Subgroup analyses by baseline HSV-1 titer
- Correlation: HSV-1 avidity vs. UPDRS change
- Correlation: inflammatory markers vs. UPDRS change
- Reviews unblinded safety data every 3 months
- Stopping rules: >5% serious adverse events in treatment arm
- Expected: mild GI symptoms, headache
- Unexpected: severe cutaneous reactions, hepatic toxicity
| Item |
Cost (USD) |
| Study coordination |
00,000 |
| Drug/placebo |
00,000 |
| Lab assays |
00,000 |
| Imaging (DaTSPECT) |
00,000 |
| Statistical analysis |
50,000 |
| Regulatory/IRB |
0,000 |
| Contingency (15%) |
80,000 |
| Total |
,380,000 |
| Milestone |
Month |
| Protocol finalization |
0 |
| IRB submission/approval |
1-3 |
| Patient enrollment |
3-15 |
| Follow-up completion |
15-27 |
| Data analysis |
27-30 |
| Publication |
30-36 |
- Informed consent from all participants
- Minimal risk design (valacyclovir is FDA-approved with known safety profile)
- Independent DSMB oversight
- Results will be shared regardless of outcome
- Significant reduction in UPDRS-III progression in treatment arm
- Decreased HSV-1 reactivation markers
- Reduced inflammatory biomarkers
- Supports clinical trial progression to Phase 3
- No difference between arms
- Inflammatory markers unchanged
- Will inform future research directions